TRACON Pharmaceuticals Inc. (TCON)

0.33
0.00 0.27
NASDAQ : Health Technology
Prev Close 0.33
Open 0.33
Day Low/High 0.31 / 0.34
52 Wk Low/High 0.29 / 1.73
Volume 317.21K
Avg Volume 106.70K
Exchange NASDAQ
Shares Outstanding 29.94M
Market Cap 9.16M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TRACON Pharmaceuticals Presents Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Soft Tissue Sarcoma Including Angiosarcoma

TRACON Pharmaceuticals Presents Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Soft Tissue Sarcoma Including Angiosarcoma

Combination Treatment Continues to Demonstrate Encouraging Signs of Activity

TRACON Pharmaceuticals Announces Positive Results From National Cancer Institute Phase 1/2 Trial Of TRC105 And Nexavar® In Hepatocellular Cancer Published In Clinical Cancer Research

TRACON Pharmaceuticals Announces Positive Results From National Cancer Institute Phase 1/2 Trial Of TRC105 And Nexavar® In Hepatocellular Cancer Published In Clinical Cancer Research

Overall response rate of 25% by RECIST and median overall survival of 15.5 months exceeds response rate and median overall survival reported in pivotal trials of single agent Nexavar